1st BRITISH BREAST CANCER RESEARCH CONFERENCE
East Midlands Conference Centre, Nottingham
15 - 17 SEPTEMBER 2010
PROGRAMME SUMMARY
Wednesday 15th September
10-45am Opening of Meeting by President
Professor Michael Kerin, University of Galway, Rep of Ireland
Plenary lectures:
New Strategies for the rational treatment of endocrine resistant tumours
Dr Rachel Schiff, Baylor College of Medicine, Houston, USA
Understanding Estrogen Receptor-mediated gene transcription in breast cancer
Dr Jason Carroll, Cancer Research UK, Cambridge, UK
Use of HER2 in elderly primary and good prognosis breast cancer
Professor Robert Leonard, Imperial College, London, UK
Lunchtime Symposium
How to personalise medicine in HER2 positive metastatic breast cancer
Chair: Dr Stephen Chan, Nottingham UK
Themed parallel sessions:
Oncoplastic Surgery
Basic Science
Pathology
Oncology
Thursday 16th September
Plenary lectures:
Oncotype DX; validation and clinical decision making
Dr Pat W Whitworth, Nashville Breast Center, Tennessee
Expanding evidence for uses of bisphosponates in managing Breast Cancer
Professor Michael Gnant, Medical University of Vienna, Austria
Health and quality of life after breast reconstruction surgery
Dr Andrea Pusic, Memorial Sloane Kettering, New York, USA
Historical Lecture
20 years of the Nottingham Breast Cancer Conference; a personal reflection
Professor Roger Blamey, Nottingham, UK
Themed workshops:
Breast Cancer in the Elderly;
Are Oncotype DX and Mammaprint ready for clinical use?
Biology of therapeutic resistance and tumour progression
Ductal Carcinoma in Situ
New Technologies in Breast Cancer Management
Oncoplastic Developments
Friday 17 September
Plenary lectures:
Breast Cancer Databases; ONCOPOOL vs SEER
Dr Johan Lundin, Helsinki, Finland
Morphological and molecular subtypes of breast cancer
Dr Jorge Reis-Filho, Breakthrough Breast Cancer Research Centre, London UK
Mechanisms of response and resistance to anti-angiogenesis therapy
Professor A Harris, Cancer Research UK Medical Oncology Dept, Oxford, UK
Themed parallel sessions:
Prognostic Factors
Surgery
Audit/Imaging
Psychology
Posters:
During the meeting there are 2 poster viewing sessions with short oral presentations of the best posters
1st BRITISH BREAST CANCER RESEARCH CONFERENCE
15 - 17 SEPTEMBER 2010
FULL PROGRAMME
President: Professor Michael Kerin
Wednesday 15th September
10.45am Welcome and opening of meeting
Meeting President - Professor Michael Kerin, University of Galway, Rep of Ireland
11.00am Plenary lecture 1
New Strategies for the rational treatment of endocrine resistant tumours
Dr Rachel Schiff, Baylor College of Medicine, Houston, USA
11.30am 4 parallel sessions - each 8 papers
Parallel Session 1 – Oncoplastic Surgery Chairman:
11.30 am
O-1 Breast skin envelope necrosis after skin sparing mastectomy and immediate breast reconstruction- how common is it?
T.Sircar, A. Choudhry, E. Katerinaki, G.Sterne
Birmingham City Hospital, Birmingham, UK
11.40 am
O-2 Skin Reducing Mastectomy and immediate reconstruction: the effect of radiotherapy on outcome.
Jo Skillman, Vijay Korwar, Robert Warner, Pilar Mate
University Hospital Birmingham, UK
11.50 am
O-3 Immediate Breast Reconstruction after Skin-Sparing Mastectomy: Analysis of 160 Consecutive Cases
Jarrar G, Salih V, Mostafa A, Gattuso J, Shenton K, Peel A, Carpenter R
Department of Breast Surgery, St Bartholomew’s Hospital, London, UK
12 noon
O-4 “Central overlap” breast reconstruction – a cosmetic and versatile anatomical implant-based technique.
Appleton ND, Barnes R, Williams RJL
Royal Glamorgan Hospital, Llantrisant, UK
12.10 pm
O-5 Efficacy of breast-volume displacement using an extended glandular flap after breast conserving surgery for Japenese women with small breast
Tomoko Ogawa
Department of Breast Surgery, Mie University Graduate School of Medicine, Japan
12.20 pm
O-6 Oncological, Clinical and Quality of Life Outcomes after Immediate Breast Reconstruction
HM Heneghan, R Lyons, C Malone, R McLaughlin, KJ Sweeney, MJ Kerin.
Department of Surgery, Galway University Hospital, Galway, Ireland.
12.30 pm
O-7 Cell-assisted lipotransfer for breast reconstruction after breast conserving therapy
Yuko Asano1 and Kotaro Yoshimura2
1 Cellport Clinic, Yokohama, Japan, 2 Department of Plastic Surgery, University of Tokyo, Japan
12.40 pm
O-8 Patient reported outcome measures are an integral part of clinical outcomes in future treatment recommendations in breast reconstruction
ZE Winters1, A Reece-Smith1, J Mills2, J McIntosh1, A Bahl3, A Nicholson3, V Balta1, HJ Thomson1.
1University of Bristol, UK
2 Clinical Trials & Statistic Unit, The Institute of Cancer Research, Sutton, UK
3University Hospitals of Bristol NHS Foundation Trust, Bristol, UK
Parallel Session 2 – Basic Science Chairman:
11.30 am
O-9 Loss of CSMD1 expression disrupts cell morphology and mammary duct formation while enhancing proliferation, migration and invasion.
Mohamed Kamal1,2, Deborah Holliday1,Valerie Speirs1,Carmel Toomes1, Sandra M Bell1
1Leeds Institute of Molecular Medicine, University of Leeds, UK.
2Faculty of Science, University of Benha, Egypt.
11.40 am
O-10 High TIMM17A expression is associated with poor clinical outcome and unfavourable pathological parameters in human breast cancer
Mohamed Salhab1, Neill Patani1, Wen Jiang2, Kefah Mokbel1
1- St George's Hospital, London, UK.
2- University Department of Surgery, Cardiff, UK.
11.50 am
O-11 Inhibiting DNA methylation and histone deacetylation enhances response to docetaxel in breast cancer cells.
Lena Kastl, Andrew C Schofield
School of Medicine and Dentistry, University of Aberdeen, UK.
12 noon
O-12 Translational Exploration of PIK3/Akt pathway activation in Early Invasive Breast Cancer
Mohammed A. Aleskandarany, Emad A. Rakha, Mohammed A Ahmed, Des G Powe, Ian O. Ellis, Andrew R. Green
Division of Pathology, Nottingham University Hospitals and University of Nottingham, Nottingham, UK
12.10 pm
O-13 D-glucuronyl C5-epimerase inhibits breast cancer cells proliferation through the tumour suppressor genes activation
T.Y. Prudnikova1, N.V. Domanitskaya 1, L.A. Mostovich1, T.V. Pavlova 2, V.I. Kashuba2,3, E.R. Zabarovsky2,4, E.V. Grigorieva1,2*
1Institute of Molecular Biology and Biophysics, Novosibirsk, Russia; 2MTC, Karolinska Institute, Stockholm, Sweden; 3Institute of Molecular Biology and Genetics, Kiev, Ukraine; 4Engelhard Institute of Molecular Biology, Moscow, Russia
12.20 pm
O-14 Expression and activation of Akt and NFkB in breast cancer patients
Edwards J, Tannahill C, OBondo C, Elsberger B, Mallon E, Wilson C Doughty J
Western Infirmary/ University of Glasgow, Glasgow, UK
12.30 pm
O-15 Upregulation of the estrogen pathway in endocrine sensitive breast cancer cells with herpceptin treatment
JG Solon, D Collins, M McIlroy, ADK Hill, L Young
Endocrine Oncology Research Group, Royal College of Surgeons of Ireland, Ireland
12.40 pm
O-16 JAMA-A: A hope for breast cancer therapy?
Gozie Offiah
Dept of Surgery, Royal College of Surgeons, Ireland
Parallel Session 3 – Pathology Chairman:
11.30 am
O-17 Borderline HER2 Protein Positive Breast Cancers Have Similar Patient Outcome Regardless of HER2 Gene Amplification Status
FFT Barros, M Aleskandarany, E Rakha, SL Watts, DG Powe, IO Ellis, AR Green
Division of Pathology, Nottingham University Hospitals and University of Nottingham, Nottingham, UK
11.40 am
O-18 PARP1 expression in Hormone Estrogen Receptor negative breast cancer: preferential expression in basal-like and HER2-positive tumours
Ahmed A Benhasouna, Andrew R Green, Des G Powe, Muhammad A Aleskandarany, Emad A Rakha and Ian O Ellis
Division of Pathology, Nottingham University Hospitals and University of Nottingham, Nottingham, UK
11.50 am
O-19 Comparison of imputation methods for missing immunohistochemical markers in a study of breast cancer prognosis
Alaa MG Ali1*, S-J Dawson2,3, F Blows2, E Provenzano3,4, C Caldas2,3,4 and Paul Pharoah1,2,
1 Department of Public Health and Primary Care, 2 Department of Oncology, University of Cambridge;
3 Cancer Research UK Cambridge Research Institute, 4 Cambridge Breast Unit, Addenbrooke’s Hospital, and NIHR Cambridge Biomedical Research Centre, Cambridge, UK
12 noon
O-20 Rates of Growth of Breast Cancer
R W Blamey, G Ball, I O Ellis
Nottingham City Hospital, Nottingham, UK
12.10 pm
O-21 Detection and Quantification of MicroRNAs in Laser Microdissected Formalin-Fixed Paraffin Embedded (FFPE) Breast Cancer Tissues
Sarkawt M Khoshnaw1, Des G Powe1, Jorge S Reis-Filho2, Ian O Ellis1, Andrew R Green1
1Department of Histopathology, University of Nottingham and Nottingham University Hospitals, Nottingham, UK
2Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
12.20 pm
O-22
A novel Artificial Neural Network based algorithm to analyse the interaction patterns existing in gene microarrays: an application to breast cancer genomic data
Christophe Lemetre, Lee James Lancashire and Graham Roy Ball
Nottingham Trent University
12.30 pm
O-23 Imprinted gene methylation in blood and risk of breast cancer
Haggarty P, Hoad G, Scott P, Simpson L, Samad A, Smyth E, Heys SD.
RINH, University of Aberdeen
12.40 pm
O-24 Investigation of BRCA1 and BRCA2 unclassified variants using RNA studies: Experiences and interesting cases from the West Midlands Regional Genetics Laboratory.
Elizabeth Perrott, Pauline K Rehal, Ana Maria Brasgoldberg, Fiona Macdonald
West Midlands Regional Genetics Laboratory, Birmingham UK
Parallel Session 4 – Oncology Chairman:
11.30 am
O-25 ER positive screen detected breast cancers (SDBC) do not require chemotherapy
Bundred, NJ1, Morris, J2, Cheung, S3, Knox, WF4, Lawrence, GM3.
Academic Departments of Surgery1, Statistics2 and Pathology4, University Hospital of South Manchester, U.K., West Midlands Cancer Intelligence Unit3, Birmingham, UK
11.40 am
O-26 Does the additional prognostic benefit of screening in early breast cancer (EBC) apply to all patients?
Mansell J, Olusegun O, Wilson CR, Angerson WJ, Doughty JC.
Western Infirmary, Glasgow, UK.
11.50 am
O-27 Epithelial proliferation (Ki67) is prognostic in symptomatic but not screen detected breast cancers (SDBC)
Bundred, NJ1, Knox, WF2, Cramer, A3, Wilson M4, Prasad R1, Morris, J5.
Academic Departments of Surgery1, Pathology2, Radiology4 and Statistics5, University Hospital of South Manchester, Departments of Histopathology & Cytogenetics3 Christie Hospital, Manchester, UK.
12 noon
O-28 Factors associated with a complete pathological response following neoadjuvant chemotherapy for Breast Cancer
Dr Angharad Pryce, Dr Weehann Pan, Miss Adele Francis, Dr Raniel Rea
University Hospital Birmingham
12.10 pm
O-29 Can ER/PR and HER2 receptor status predict complete pathological response after neo adjuvant chemotherapy in patients with breast cancer
T Sircar, R Athwal, H Brown, D Rea, F Hoar
Birmingham City Hospital, Birmingham
12.10 pm
O-30 Basal-like phenotype is a prognostic marker of locally advanced breast cancer but not a predictive marker of response to neoadjuvant anthracycline chemotherapy
M. Shehata, A. Mukherjee, P. Moseley, E. Rakha , I. Ellis, S. Chan
Nottingham University Hospitals, Nottingham, UK
12.30 pm
O-31 Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patient
Gounaris I1, Hiller L2, Vallier A-L1, Sinnatamby R1, Provenzano E1, Iddawela M1, Wallis M1, Wishart G1 and Earl H1
1Addenbrookes Hospital, Cambridge, 2University of Warwick, Coventry, UK
12.40 pm
O-32 D-dimer as a marker for early progression in patients commencing neoadjuvant chemotherapy
Kirwan CC, McCollum CN, Bundred NJ, Byrne GJ.
University Department of Surgery, University Hospital of South Manchester, UK
1.00pm LUNCH
1.15 - 2.2pm GSK Educational Symposium - Conference Suite 3
“How to personalise medicine in HER2+ Metastatic Breast Cancer”
1.15-1.20 pm
Introduction
Dr. S Chan (Chair), Nottingham University Hospital, UK
1.20-1.45 pm
Personalised Medicine - Predictive tests for individualisation of treatment
Professor John Bartlett, Western General Hospital, UK
1.45-2.15 pm
Changes to the treatment paradigm of HR+/HER2+ disease – enabling the right patient to receive the right medicine at the right time
Professor David Cameron, Western General Hospital, UK
2.15-2.20 pm
Q&A
2.30pm Plenary Lecture 2
Understanding Estrogen Receptor-mediated gene transcription in breast cancer
Dr Jason Carroll, Cancer Research UK, Cambridge, UK
3.00 pm
O-33 An artificial neural network based algorithm for predicting continuous time to event data in breast cancer
Lee Lancashire, Andy Sutton, Robert Rees, Graham Ball
Campandia Ltd/Nottingham Trent University
3.15 pm
O-34 Dynamic Contrast-Enhanced MRI reveals core signalling pathways in
Breast Cancer
S Mehta1, NP Hughes2,4, FM Buffa1, RF Adams3, SS Gambhir2,5, AL Harris1
1Weatherall Institute of Molecular Medicine, 2Institute of Biomedical Engineering, University of Oxford
3Oxford Breast Imaging Centre, Churchill Hospital, Oxford, UK
4Molecular Imaging Program, 5Department of Bioengineering, Stanford University, USA
3.30 pm
O-35 SerpinB3, a biomarker of taxane benefit in breast cancer
Elaina SR Collie-Duguid1, Kathleen Sweeney1, Keith Stewart2, Iain Miller2, Steve Heys1
Cancer Medicine1 and Department of Pathology2, University of Aberdeen, UK
3.45 pm
O-36 Recruitment of insulin receptor substrate-1 by erbB3 impacts on IGF-IR signalling in oestrogen receptor-positive breast cancer cells
Knowlden JM1,Gee JMW1, Barrow D, Robertson JF, Ellis IO, Nicholson RI 1, Hutcheson IR1
1Tenovus Centre for Cancer Research, Cardiff University, UK
2Professorial Unit of Surgery, Nottingham City Hospital, Nottingham, UK
4.00 pm
O-37 SOX11 and PSMD3 Expression in HER2 Positive Breast Cancer
Y Pang1, GR Ball2, EA Rakha1, DG Powe1, C Caldas3, IO Ellis1, AR Green1
1Division of Pathology, Nottingham University Hospitals and University of Nottingham, Nottingham, UK
2School of Biomedical and Natural Sciences, Nottingham Trent University, UK
3Cancer Research UK, Cambridge Research Institute, Cambridge, UK
4.15 pm
O-38 Dysregulated cancer-specific miRNAs in the circulation of breast cancer patients
NA Healy, HM Heneghan, AJ Lowery, Miller N, MJ Kerin
Department of Surgery, National University of Ireland, Galway, Ireland
4.30pm TEA
5.00pm Plenary lecture 3
Use of HER II in elderly primary and good prognosis breast cancer
Professor Robert Leonard, Imperial College, London, UK
5.30 pm
O-39 HER2 positive early breast cancers: What proportion are receiving adjuvant Trastuzumab therapy? A multicentre audit.
S Marla1, J Cardale2, DJ Dodwell2, AI Skene3, O Gojis5, P Abram4, C Palmieri5, SJ Cleator6, A Bowman7, JC Doughty1
Glasgow1 Leeds2 Bournemouth3 Belfast4 Charing Cross5 St. Mary’s6 Edinburgh7, UK
5.45 pm
O-40 Breast Cancer Treatment in the Elderly.
Ian Monypenny, Sidhu, J; Lagord, C; Kearins, O; Cheung, S; Lawrence, G
University Hospital of Wales, Cardiff and the West Midlands Cancer Intelligence Unit, Birmingham
6.00 pm
O-41 Age specific breast cancer relative survival in the East of England
Alaa MG Ali1*, Gordon Wishart2, David Greenberg3 and Paul Pharoah1,4
1 Department of Public Health and Primary Care, 4 Department of Oncology, University of Cambridge;
2 Cambridge Breast Unit, Addenbrooke’s Hospital; 3 Eastern Cancer Registration and Information Centre, Cambridge, UK
6.15 pm
O-42 Early operable primary breast cancer in older (≥70 years) women (EPCs) – Biology and clinical significance
BM Syed, W Al-khyatt, AR Green*, EC Paish*, DAL Morgan**, IO Ellis*, KL Cheung
Division of Breast Surgery and *Pathology, University of Nottingham, and ** Department of Oncology, Nottingham University Hospitals, Nottingham
6.30pm Poster Session A viewing 4 groups x 12 posters (posters 1 - 48)
7.30pm BUFFET
Thursday 16th September
8.30 am Poster Session A Presentations
9.30am Historical Lecture
20 years of the Nottingham Breast Cancer Conference; a personal reflection
Professor Roger Blamey, Nottingham, UK
10.00am Invited lecture 4
Oncotype DX; validation and clinical decision making
Dr Pat W Whitworth, Nashville Breast Center, Tennessee
10.30 am
O-43 A KRAS microRNA binding site variant is a genetic marker of risk for triple negative breast cancer
HM Heneghan1, N Miller1, T Paranjape3, FJ Slack2, JB Weidhaas3,MJ Kerin1
1Department of Surgery, National University of Ireland, Galway, Ireland.
2Department of Molecular, Cellular and Developmental Biology, 3Department of Therapeutic Radiology, Yale University, USA
10.45 am
O-44 Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study
Ruth C Travis, Gillian K Reeves, Jane Green, Diana Bull, Sarah J Tipper, Krys Baker, Valerie Beral, Richard Peto, John Bell, Diana Zelenika, Mark Lathrop, for the Million Women Study Collaborators
Cancer Epidemiology Unit, University of Oxford
11.00 am
O-45 Childhood adiposity and breast cancer incidence in women in middle age
Benjamin J. Cairns, TienYu Owen Yang, Gillian K. Reeves and Valerie Beral, on behalf
of the Million Women Study Collaborators
Cancer Epidemiology Unit, University of Oxford, Oxford , UK
11.15am COFFEE
11.45am Invited lecture 5
Expanding evidence for uses of bisphosponates in managing Breast Cancer
Professor Michael Gnant, Medical University of Vienna, Austria
12.15 pm
O-46 Macrophage infiltration is associated with poor outcome in breast cancer patients and a reduced treatment response to Letrozole and Zoledronate
Lee A, Lamb R, Gregson H, Cramer A, Morris J, Renshaw L, Winter M, Coleman RE, Dixon JMJ, Landberg G, Bundred NJ.
Breakthrough Breast Centre, Manchester, UK
12.30 pm
O-47 The BASO II Trial at median 15 years of follow-up
R W Blamey and A Oates (data manager) on behalf of the Contributors to BASO II
Nottingham City Hospital
12.45 pm
O-48 The Post-operative Radiotherapy In Minimum-risk Elderly (PRIME) randomised trial of adjuvant radiotherapy after breast conserving surgery: impact on Quality of Life and Cost-effectiveness at five years
Kunkler IH1, Williams LJ2, Prescott RJ2, King CC2, Jack W1, Dixon JM1, van der Pol M3, Goh TT3, Lindley R4, Cairns J5
1 Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK, 2 Centre for Population Health Sciences, University of Edinburgh, UK, 3 Health Economics Research Unit, University of Aberdeen, UK, 4 Westmead Hospital, University of Sydney, Australia, 5 London School of Hygiene and Tropical Medicine, London, UK
1.00 pm
O-49 The influence of patient-related and surgical factors on overall cosmesis and late toxicity after adjuvant breast radiotherapy: results from the Cambridge Intensity Modulated Radiotherapy (IMRT) Trial
Gillian C Barnett1 BMBCh, Gordon C Wishart2 MD, Jennifer C Wilkinson3 BSc, Anne M Moody3 MB BChir, Charles B Wilson3 MD, Nicola Twyman3 MSc, Neil G Burnet1 MD, Charlotte E Coles3 PhD.
1 University of Cambridge Department of Oncology, 2 Cambridge Breast Unit, 3 Oncology Centre, Addenbrooke’s Hospital, Cambridge, UK.
1.15 pm
O-50 TARGIT (Targeted intra-operative radiotherapy for early stage breast cancer): Results from the TARGIT A randomized controlled trial
Michael Baum1, Jayant S Vaidya1, Jeffrey S Tobias1, Mohammed Keshtgar1, Norman R Williams1, Frederik Wenz2, Max Bulsara3, Christobel Saunders4 and David Joseph4 on behalf of the TARGIT Trialists’ Group.
1 UCL, London, UK; 2 Universitätsmedizin Mannheim, Germany; 3 University of Notre Dame, Fremantle, Australia; 4 Sir Charles Gairdner Hospital, Perth, Australia.
1.30pm LUNCH
2.30pm - 4.30pm (4.45pm) 6 Workshops
2.30pm - 4.30pm (4.45pm) 6 Workshops
a. Breast Cancer in the Elderly CHAIR: Professor R Leonard
2.30 High Breast Cancer Death Rates in Older Women in UK- Tony Moran
2.50 Screening + over diagnosis – tbc
3.10 Treatment Strategies - Alistair Ring
3.30 Attitudes of patients and clinicians - Prof Lesley Fallowfield
3.50 O-51 Clinical outcome of patients managed in a dedicated Primary Breast Cancer Clinic for Older Women (the Clinic)
KL Cheung1, BM Syed1 , SJ Johnston1, L Winterbottom2, H Kennedy2, DAL Morgan3
1 Division of Breast Surgery, University of Nottingham; 2 Nottingham Breast Institute and 3 Department of Oncology, Nottingham University Hospitals, Nottingham, UK
4.00 O-52 East of England breast cancer survival close to best in Europe
Wishart GC1,3, Caldas C1,3, Brown CH2, Greenberg DC2
Cambridge Breast Unit, Cambridge, UK
4.10 O-53 A study of the value of comprehensive geriatric assessment (CGA) in older women with primary breast cancer – Preliminary results
L Hall, SW Tang, A Hurria1, L Winterbottom2, H Kennedy2, DAL Morgan3, D Porock2, KL Cheung
Division of Breast Surgery and 2School of Nursing, University of Nottingham, UK; 1Cancer and Aging Research Program, City of Hope, Durate, USA; 2Nottingham Breast Institute and 3Department of Oncology, Nottingham University Hospitals, Nottingham, UK
b. Are Oncotype DX and Mammaprint ready for clinical use? CHAIR: James Mackay
2.30 Gene profiling tests - Kathy Albain
2.50 Mammaprint –Professor S Rodenhuis
3.10 A surgical viewpoint on how to use this new information - Gerald Gui
3.30 What does the health insurer do with this new information - Dr.V Warren (Assist Med Director BUPA) - tbc
3.50 What does the pathologist do with this new information - tbc
c. Biology of therapeutic resistance and tumour progression CHAIR: Val Speirs
2.30 Tumour progression - Erik Sahai
3.00 Stem cells and resistance - Gillian Farnie
3.30 O-54 Involvement of miR-34a in resistance of breast cancer cells to docetaxel.
Lena Kastl, Andrew C Schofield
School of Medicine and Dentistry, University of Aberdeen, UK
3.40 O-55 Translational landscape of Epithelial Mesenchymal Transition in Molecular Classes of Invasive Breast Cancer
Mohammed A. Aleskandarany1, Andrew R. Green1 , Emad A. Rakha 2, Des G Powe2, Ian O. Ellis1,2
1Division of Pathology, University of Nottingham, UK, 2Department of Pathology, Nottingham University Hospitals, UK
3.50 O-56 High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1 and ERK-1/2 is associated with development of tamoxifen resistance in ER positive breast cancer patients
Carol Watson1, Jaclyn S. Long2, Clare Orange3, Claire L Tannahill1, Elizabeth Mallon3, Liane M. McGlynn1, Susan Pyne2, Nigel J Pyne2 and Joanne Edwards1.
University of Glasgow
d. DCIS CHAIR: Hugh Bishop
2.30 Variation of practice in Europe - J Lundin
2.45 What have we learnt about the radiology of DCIS - H Dobson
3.00 The Pathology of DCIS- routine present practise - J Thomas
3.15 New understanding of molecular pathology and progression of DCIS - L Jones
3.30 Margins,nodes and rays; the clarity of present UK practise as revealed by the
Sloane Project - S Nicholson
3.45 Future DCIS management - where do we go from here? -Prof N Bundred
4.00 O-57 Screen Detected DCIS in The East Midlands Region: Comparisons in Treatment and Outcome Over Time (1988-2003)
Reed JA¹, Murphy A¹, Comerie G¹, Sibbering DM²,
East Midlands Quality Assurance (QA) Reference Centre, Nottingham, UK¹
Royal Derby Hospital, Derby, UK²
4.10 O-58 Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma insitu
Mathew J, Karia R, Warrich N, Morgan D*, Lee A**, Ellis I**, Robertson J, Bello A
Division of Breast Surgery , Department of Oncology* and Department of Pathology**, Nottingham University Hospitals, Nottingham, UK Summary : Hugh Bishop
4.25 Summary : Hugh Bishop
e. New Technologies in Breast Cancer Management CHAIR: Prof R Mansel
2.30 Sentinel Node : pre-operative and intra-operative developments;
2.45 Pre-operative identification and needle biopsy of the sentinel
lymph node using microbubbles - P Jones
3.00 ICG Fluorescence emissions - G Wishart
3.15 OSNA - M Kissin
3.25 Intra-operative and brachytherapies – J Vaidya
3.45 Microwave ablation of small tumours – R Mansel
4.00 O-59 Single centre experience of 500 patients with intra-operative RT-PCR breast sentinel node analysis
Brown V, Cutress R, Simoes T, Agrawal A, Wise M, Cree I and Yiangou C
Portsmouth Breast Cancer Centre, Queen Alexandra Hospital Portsmouth
4.10 O-60 One-step nucleic acid amplification in detection of lymph node metastases in breast cancer patients: Are patients being over treated?
Madani R1, Jafferbhoy S1, Thwaites L2, Jackson P2, Layer GT1, Irvine TE1, Kissin MW1
1) Department of Breast and Oncoplastic surgery, 2) Department of Histopathology
Royal Surrey County Hospital, Guildford
4.20 O-61 Argon Beam Coagulator in breast surgery: effect on the incidence of breast seroma
V Lefemine, W Samra
Glan Clwyd Hospital, Rhyl, UK
f. Oncoplastic Developments CHAIR: D Macmillan
Session 1-Training in OPBS X3 20 min (10 - 15 min talks)
2.30 What's new about the new breast curriculum?: Fiona Macneill
2.45 National oncoplastic fellowships: a SWOT analysis of the first 8 years: Anne Tansley
3.00 The new MS in oncoplastic breast surgery: Jerome Pereira
Session 2- Measuring outcomes in OPBS X3 20 min (10 - 15 min talks)
3.15 Clinical outcomes and the NMBRA- how can we do better?: Jerome Pereira
3.30 PROMS and the NMBRA- what do these new tools show?: Ranjeet Jeevan
3.45 Future challenges: Dick Rainsbury
4.00 O-62 Oncoplastic Surgery: Who is doing what?
J Skillman (UHCW), Lisa Whisker, D England, M Hallissey
University Hospital, Birmingham, UK
4.10 O-63 Oncoplastic outcomes with implant based breast reconstruction and radiotherapy: An 8 year retrospective analysis
Ciara McGoldrick1, Darren Brady2, Stephen Sinclair1
Regional Plastic and Maxillofacial Unit, Ulster Hospital Dundonald, Cancer Centre, Belfast City Hospital
4.20 O-64 Attitudes of Breast and Plastic Surgeons to Lipomodelling in Breast Surgery
Jo Skillman (University Hospital Coventry and Warwickshire), Lisa Whisker, D England, M Hallissey University Hospital Birmingham, UK
4.30pm TEA and Poster Session B viewing 4 groups x 12 posters (posters 49 - 96)
2.30pm - 4.30pm (4.45pm) 6 Workshops
a. Breast Cancer in the Elderly CHAIR: Professor R Leonard
2.30 High Breast Cancer Death Rates in Older Women in UK- Tony Moran
2.50 Screening + over diagnosis – tbc
3.10 Treatment Strategies - Alistair Ring
3.30 Attitudes of patients and clinicians - Prof Lesley Fallowfield
3.50 O-51 Clinical outcome of patients managed in a dedicated Primary Breast Cancer Clinic for Older Women (the Clinic)
KL Cheung1, BM Syed1 , SJ Johnston1, L Winterbottom2, H Kennedy2, DAL Morgan3
1 Division of Breast Surgery, University of Nottingham; 2 Nottingham Breast Institute and 3 Department of Oncology, Nottingham University Hospitals, Nottingham, UK
4.00 O-52 East of England breast cancer survival close to best in Europe
Wishart GC1,3, Caldas C1,3, Brown CH2, Greenberg DC2
Cambridge Breast Unit, Cambridge, UK
4.10 O-53 A study of the value of comprehensive geriatric assessment (CGA) in older women with primary breast cancer – Preliminary results
L Hall, SW Tang, A Hurria1, L Winterbottom2, H Kennedy2, DAL Morgan3, D Porock2, KL Cheung
Division of Breast Surgery and 2School of Nursing, University of Nottingham, UK; 1Cancer and Aging Research Program, City of Hope, Durate, USA; 2Nottingham Breast Institute and 3Department of Oncology, Nottingham University Hospitals, Nottingham, UK
b. Are Oncotype DX and Mammaprint ready for clinical use? CHAIR: James Mackay
2.30 Gene profiling tests - Pat Whitworth
2.50 Mammaprint –Professor S Rodenhuis
3.10 A surgical viewpoint on how to use this new information - Gerald Gui
3.30 What does the health insurer do with this new information - Dr.V Warren (Assist Med Director BUPA)
3.50 What does the pathologist do with this new information - tbc
c. Biology of therapeutic resistance and tumour progression CHAIR: Val Speirs
2.30 Tumour progression - Erik Sahai
3.00 Stem cells and resistance - Gillian Farnie
3.30 O-54 Involvement of miR-34a in resistance of breast cancer cells to docetaxel.
Lena Kastl, Andrew C Schofield
School of Medicine and Dentistry, University of Aberdeen, UK
3.40 O-55 Translational landscape of Epithelial Mesenchymal Transition in Molecular Classes of Invasive Breast Cancer
Mohammed A. Aleskandarany1, Andrew R. Green1 , Emad A. Rakha 2, Des G Powe2, Ian O. Ellis1,2
1Division of Pathology, University of Nottingham, UK, 2Department of Pathology, Nottingham University Hospitals, UK
3.50 O-56 High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1 and ERK-1/2 is associated with development of tamoxifen resistance in ER positive breast cancer patients
Carol Watson1, Jaclyn S. Long2, Clare Orange3, Claire L Tannahill1, Elizabeth Mallon3, Liane M. McGlynn1, Susan Pyne2, Nigel J Pyne2 and Joanne Edwards1.
University of Glasgow
d. DCIS CHAIR: Hugh Bishop
2.30 Variation of practice in Europe - J Lundin
2.45 What have we learnt about the radiology of DCIS - H Dobson
3.00 The Pathology of DCIS- routine present practise - J Thomas
3.15 New understanding of molecular pathology and progression of DCIS - L Jones
3.30 Margins,nodes and rays; the clarity of present UK practise as revealed by the
Sloane Project - S Nicholson
3.45 Future DCIS management - where do we go from here? -Prof N Bundred
4.00 O-57 Screen Detected DCIS in The East Midlands Region: Comparisons in Treatment and Outcome Over Time (1988-2003)
Reed JA¹, Murphy A¹, Comerie G¹, Sibbering DM²,
East Midlands Quality Assurance (QA) Reference Centre, Nottingham, UK¹
Royal Derby Hospital, Derby, UK²
4.10 O-58 Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma insitu
Mathew J, Karia R, Warrich N, Morgan D*, Lee A**, Ellis I**, Robertson J, Bello A
Division of Breast Surgery , Department of Oncology* and Department of Pathology**, Nottingham University Hospitals, Nottingham, UK Summary : Hugh Bishop
4.25 Summary : Hugh Bishop
e. New Technologies in Breast Cancer Management CHAIR: Prof R Mansel
2.30 Sentinel Node : pre-operative and intra-operative developments;
2.45 Pre-operative identification and needle biopsy of the sentinel
lymph node using microbubbles - P Jones
3.00 ICG Fluorescence emissions - G Wishart
3.15 OSNA - M Kissin
3.25 Intra-operative and brachytherapies – J Vaidya
3.45 Microwave ablation of small tumours – R Mansel
4.00 O-59 Single centre experience of 500 patients with intra-operative RT-PCR breast sentinel node analysis
Brown V, Cutress R, Simoes T, Agrawal A, Wise M, Cree I and Yiangou C
Portsmouth Breast Cancer Centre, Queen Alexandra Hospital Portsmouth
4.10 O-60 One-step nucleic acid amplification in detection of lymph node metastases in breast cancer patients: Are patients being over treated?
Madani R1, Jafferbhoy S1, Thwaites L2, Jackson P2, Layer GT1, Irvine TE1, Kissin MW1
1) Department of Breast and Oncoplastic surgery, 2) Department of Histopathology
Royal Surrey County Hospital, Guildford
4.20 O-61 Argon Beam Coagulator in breast surgery: effect on the incidence of breast seroma
V Lefemine, W Samra
Glan Clwyd Hospital, Rhyl, UK
f. Oncoplastic Developments CHAIR: D Macmillan
Session 1-Training in OPBS X3 20 min (10 - 15 min talks)
2.30 What's new about the new breast curriculum?: Fiona Macneill
2.45 National oncoplastic fellowships: a SWOT analysis of the first 8 years: Anne Tansley
3.00 The new MS in oncoplastic breast surgery: Jerome Pereira
Session 2- Measuring outcomes in OPBS X3 20 min (10 - 15 min talks)
3.15 Clinical outcomes and the NMBRA- how can we do better?: Jerome Pereira
3.30 PROMS and the NMBRA- what do these new tools show?: Ranjeet Jeevan
3.45 Future challenges: Dick Rainsbury
4.00 O-62 Oncoplastic Surgery: Who is doing what?
J Skillman (UHCW), Lisa Whisker, D England, M Hallissey
University Hospital, Birmingham, UK
4.10 O-63 Oncoplastic outcomes with implant based breast reconstruction and radiotherapy: An 8 year retrospective analysis
Ciara McGoldrick1, Darren Brady2, Stephen Sinclair1
Regional Plastic and Maxillofacial Unit, Ulster Hospital Dundonald, Cancer Centre, Belfast City Hospital
4.20 O-64 Attitudes of Breast and Plastic Surgeons to Lipomodelling in Breast Surgery
Jo Skillman (University Hospital Coventry and Warwickshire), Lisa Whisker, D England, M Hallissey University Hospital Birmingham, UK
5.30pm Invited lecture 6
Health and quality of life after breast reconstruction surgery
Dr Andrea Pusic, Memorial Sloane Kettering, New York, USA
6.00pm Something Else
Mr Mark Kissin, Guildford, UK
7.30pm RECEPTION
8.00pm CONFERENCE DINNER
Friday 17 September
8.30am Poster Session B Presentations
9.30 am Invited lecture 7
Breast Cancer Databases; ONCOPOOL vs SEER
Johan Lundin, Finland
10.00am COFFEE
10.30am Invited lecture 8
Morphological and molecular subtypes of breast cancer
Dr Jorge Reis-Filho, Breakthrough Breast Cancer Research Centre, London, UK
11.00am 4 parallel sessions - each 8 papers
Parallel session 5 – Prognostic Factors Chairman:
11.00 am
O-65 The relationship between biomarkers of inflammation, clinicopathological characteristics and cancer specific survival in early breast cancer
Obondo CA, Mansell J, Al Murri AM, Lannigan A, Doughty JC and McMillan DC
University Department of Surgery, Royal Infirmary, Glasgow, UK
11.10 am
O-66 Reduced MCPH1 expression in breast cancer is associated with reduced survival in ductal carcinomas
Julie Richardson1, Abeer M. Shaaban2, Mohamed Kamal1, Ian Ellis3, Valerie Speirs1 Andrew Green3 and Sandra M. Bell1
1Leeds Institute of Molecular Medicine, University of Leeds, 2St James’s Institute of Oncology, St James’s University Hospital, Leeds, UK
3Department of Pathology, Nottingham University Hospitals, UK
11.20 am
O-67 Assessments of Proliferation in Breast Cancer
Sundquist M, Brudin L, Kovacs A, Mathe G, Tejler G, Thorstenson S
Kalmar County Hospitals and Sahlgrenska University Hospital, Gothenburg, Sweden
11.30 am
O-68 The effect of Lymphovascular Invasion (LVI) on Survival
Blamey RW, Sundquist M, Bianchi S, Douglas-Jones A, Ellis IO, Lee AHS, Pinder S, Thorstenson S, Ball GR,
On behalf of the ONCOPOOL Consortium
11.40 am
O-69 Predicting the probability of outcome in breast cancer - A Comparison of Different Machine Learning Methods
Mrs A. Al-allak, Pro. R. Leonard & Dr P. Lewis
Institute of Life Science, School of Medicine, Swansea University, UK
11.50 am
O-70 Comparison of PREDICT and ADJUVANT! Prognostication models for early breast cancer in a UK dataset
GC Wishart, Helen Campbell, EM Azzato, DC Greenberg, J Rashbass, C Caldas, PDP Pharoah
Cambridge Breast Unit, UK
12 noon
O-71 Rescoring of grade and re-evaluation of the Nottingham Prognostic Index (NPI) using components of Elston Ellis grade and adding lympho-vascular invasion
Blamey R W, Ball G R., Lee A.H.S, Bianci S, Green A, Hornmark-Stanstam B, Kuukasjarvi T, Pinder S, Rank F, Ellis I O
Nottingham City Hospital and the ONCOPOOL Consortium
12.10 pm
O-72 Remodeling the Nottingham Prognostic Index (NPI) for individual prognosis
G Ball, C. Lemetre, A.R. Green, I.O. Ellis, R. Blamey.
Nottingham Trent University
Parallel session 6 – Surgery Chairman:
11.00 am
O-73 Sentinel node biopsy may be more sensitive for detecting positive nodes than axillary node sample: results from a retrospective analysis
Macaskill EJ, Brauer K, Purdie CA and Brown DC
Department of Breast Surgery, Department of Breast Radiology, Ninewells Hospital, Dundee, UK
11.10 am
O-74 How often does a positive sentinel lymph node biopsy prompt an isolated delayed axillary lymph node dissection?
Benson JR, Wishart GC, Forouhi P, Provenzano E.
Cambridge Breast Unit, Addenbrooke’s Hospital, Cambridge, UK
11.20 am
O-75 Fine Needle Aspiration Cytology is a valuable adjunct to axillary ultrasound in the preoperative staging of early breast cancer
Morna MacNeill, Isobel Arnott and Jeremy Thomas
Edinburgh Breast Unit, Edinburgh, UK
11.30 am
O-76 Breast radiotherapy for occult breast cancer with axillary nodal metastases – does it reduce local recurrence rate and increase overall survival?
S Masinghe, O Faluyi, G Kerr, I Kunkler
Western General Hospital, Edinburgh
11.40 am
O-77 Sentinel Lymph Node Biopsy (SLNB) Before Primary Chemotherapy (PC) In Breast Cancer Patients
Benson JR, Wishart GC, Ambler G, Provenzano E.
Cambridge Breast Unit, Addenbrooke’s Hospital, Cambridge, UK
11.50 am
O-78 Comparison between endoscope-assisted partial mastectomy with filling of
dead space using absorbable mesh and conventional conservative method on
cosmetic outcome in patients with stage 1 & 2 breast cancer
Nobuyuki Takemoto, Ai Koyanagi *
Department of Breast & Endocrine Surgery, Japan Medical Alliance Higashi
Saitama General Hospital, Japan
*Department of Global Health Policy, University of Tokyo, Japan
12 noon
O-79 Effect of Lymphovascular Invasion (LVI) on Local Recurrence after Wide Local Excision (WLE) and after Mastectomy (Mx)
Blamey RW, Cataliotti L, Sundquist M, Mansel R, Ball GR
On behalf of the ONCOPOOL Consortium
12.10 pm
O-80 Lobular Neoplasia & Conservative surgical management
Mr.B.S.Mothe, Miss Tani Fasih, Mr. David Browell, Mr.Kevin Clark;
Queen Elizabeth Hospital, Gateshead, UK
Parallel session 7 – Audit/Imaging Chairman:
11.00 am
O-81 The impact of caseload on practice patterns in breast cancer; evidence from the UK Breast Screening Programme
Glynn RW1, Marshall N1, Coffey N2, Kearins O3, Lawrence G3, Bishop H4, Kerin MJ1
1Dept. of Surgery, National University of Ireland Galway, 2Dept. of Biostatistics, National University of Ireland Galway, 3West Midlands Cancer Intelligence Unit, 4Department of Breast Surgery, Royal Bolton Hospital
11.10 am
O-82 The influence of mode of presentation on the pattern of recurrence in early breast cancer (EBC)
Mansell J, Wilson CR, Angerson WJ, Doughty JC.
Western Infirmary, Glasgow, UK
11.20 am
O-83 Digital infrared imaging for breast cancer detection in younger women undergoing breast biopsy
Wishart GC, Campisi MS, Chapman D, Shackleton V, Iddles S, Hallett A, Britton PD.
Cambridge Breast Unit, Cambridge, UK
11.30 am
O-84 An observer performance study comparing the interpretation of full-field digital mammography with digital breast tomosynthesis.
Dr. Rema K. Wasan, Dr. Asif Iqbal, Dr. David R. Evans, Dr. Clare Peacock, Dr. Juliet C. Morel, Dr. Abdel Douiri, Dr. Michael J. Michell.
King's College Hospital. &King's College London
11.40 am
O-85 What do clinicians in the UK do once a patient has received 5 years of adjuvant hormonal Aromatase Inhibitor (AI) containing treatment?
Claire Gaunt, Daniel Rea
CRUK Clinical Trials Unit University of Birmingham
11.50 am
O-86 Mastectomy and Reconstruction in Stage IV Breast Cancer: A Survey of UK Breast and Plastic Surgeons
CAT Durrant1, M Khatib1, FA MacNeill2, SE James1, PA Harris1
1 Dept. Plastic Surgery, 2 Dept. Breast Surgery, Royal Marsden Hospital, London, UK
12 noon
O-87 Research output of consultant breast surgeons in the UK and Ireland – a bibliographic analysis
Glynn RW, Healy NA, Sweeney KJ, Kerin MJ.
Department of Surgery, National University of Ireland Galway
12.10 pm
O-88 Breast cancer among Nigerian women: Clinical and Biological Differences compared with age-matched UK women
J Agboola1,2, AA Banjo2, N Wanangwa1, S El-Sheikh1, EA Rakha1, EC Paish1, S Watts1, DG Powe1, IO Ellis1, AR Green1
1Division of Pathology, Nottingham University Hospitals and University of Nottingham, UK.
2Dept of Morbid Anatomy and Histopathology, Olabisi Onabanjo University and Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria
Parallel session 8 – Psychology Chairman:
11.00 am
O-89 The Influence of Childhood Abuse on Clinical Relationships in Breast Cancer: Perceived Professional Support, Clinician-Rated ‘Difficulty’ and Insecure Attachment.
Miss Louise Clark1, Mr Chris Holcombe2, Dr Helen Beesley2, Professor Peter Salmon1
1Division of Clinical Psychology, University of Liverpool. 2Royal Liverpool University Hospital, UK
11.10 am
O-90 The NHS Breast Screening Programme – Are we communicating well with South Asian Origin Women?
Jain AK 1, Acik- Toprak N 2, Serevitch, J 1 and Nazroo, J 2
1 The Nightingale Centre, University Hospital of South Manchester; 2 Department of Sociology, University of Manchester, UK
11.20 am
O-91 Characterising Post-mastectomy Pain Syndrome in 111 Scottish women
Sheridan, David1, Foo, Irwin2, O'Shea, Halia2, Fallon, Marie3, Colvin, Lesley2
1School of Biomedical Sciences, University of Edinburgh, 2Department of Anaesthesia critical care and Pain Medicine, Western General Hospital, Edinburgh, 3Edinburgh Cancer centre, Univ of Edinburgh
11.30 am
O-92 A Multi centre prospective longitudinal study evaluating Health related quality of life after immediate Latissimus dorsi (LD) breast reconstruction
ZE Winters1, J Mills2, J Haviland2, A Reece-Smith1, M Greenslade1, J Benson3, M Galea4, P McManus5, S Nicholson6, E Weiler-Mithoff7, Z Rayter1, V Balta1, HJ Thomson1
University Hospitals, Bristol 1, Clinical Trials & Statistics Unit, The Institute of Cancer Research, Sutton2, Addenbrooke’s Hospital, Cambridge 3, Great Western Hospital, Swindon4, Hull and East Yorkshire Hospitals 5, York Hospitals 6, Greater Glasgow and Clyde, Canniesburn7
11.40 am
O-93 The development of an EORTC breast reconstruction questionnaire to assess the quality of life of patients undergoing breast reconstruction
ZE Winters1, J Mills2, Y Brandberg3, F Didier4, A Oberguggenberger5,
HJ Thomson1 on behalf of the EORTC Quality of Life group
1 University of Bristol, UK; 2 Clinical trials & Statistic Unit, Institute of Cancer Research, Sutton, UK;
3 Karolinska Institute, Stockholm, Sweden; 4 European Institute of Oncology, Milan, Italy; 5 Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Austria
11.50 am
O-94 Patient Reported Outcomes following Post Mastectomy Breast Reconstruction
Massey E, Price R, Betambeau N, Tydeman C, Galea M
The Great Western Hospital, Swindon
12 noon
O-95 RCT evaluating the effect of mindfulness-based stress reduction (MBSR) on mood, quality of life and wellbeing in women with stages 0 to III breast cancer
Dr Caroline Jane Hoffman
Breast Cancer Haven & University of Southampton
12.10pm
O-96 Using a needs assessment tool in breast cancer follow-up
Susanne Cruickshank, D M Barber, Prof C Kennedy, Dr A. Rowat, R Small
Edinburgh Napier University
12.30pm
Plenary lecture 9
Professor A Harris
Mechanismsof response and resistance to anti-angiogenesis therapy
1.00pm Best paper prize
CLOSE
